INTEGRA LIFESCIENCES HOLDINGS CORP

For the period ended Sep 30, 2026. Filed Oct 23, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 23, 2026

IART$14.53+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME (LOSS)

(Dollars in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Total revenue, net	$411,182	$402,062	$1,221,861	$1,200,320
Costs and expenses:
Cost of goods sold	201,316	195,071	575,269	589,565
Research and development	21,897	22,456	69,651	74,181
Selling, general and administrative	165,311	169,046	515,982	530,433
Intangible asset amortization	3,758	3,728	11,304	11,186
Goodwill impairment charge	—	—	—	511,365
Total costs and expenses	392,282	390,301	1,172,206	1,716,730
Operating income (loss)	18,900	11,761	49,655	(516,410)
Interest income	5,002	4,982	13,375	14,112
Interest expense	(22,961)	(22,725)	(68,419)	(62,582)
Other income (expense), net	14,723	(842)	23,388	(2,932)
Income (loss) before income taxes	15,664	(6,824)	17,999	(567,812)
Provision (benefit) for income taxes	812	(1,420)	3,282	(53,042)
Net income (loss)	$14,852	$(5,404)	$14,717	$(514,770)
Net income (loss) per share
Basic	$0.19	$(0.07)	$0.19	$(6.72)
Diluted	$0.19	$(0.07)	$0.19	$(6.72)
Weighted average common shares outstanding (See Note 12):
Basic	77,387	76,753	77,210	76,637
Diluted	78,577	76,753	77,941	76,637
Comprehensive income (loss) (See Note 13)	20,536	(6,472)	10,281	$(519,174)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.